Cognition Therapeutics is advancing CT1812, a novel oral treatment targeting synaptic density in patients with mild to moderate Alzheimer's disease. The Alzheimer's disease market is projected to grow significantly, driven by increasing prevalence and demand for effective therapies. With a focus on synaptic health, CT1812 may differentiate itself from existing treatments by addressing cognitive decline through a unique mechanism. Competitive analysis indicates a crowded landscape with several anti-amyloid and tau-targeting therapies; however, CT1812's distinct approach may provide a strategic advantage. Diligence considerations should include the safety profile, regulatory pathway, and potential for partnerships or licensing agreements, particularly given the involvement of the National Institute on Aging (NIA) as a collaborator.